Collectively, the beneficial effects of APZ in post-stroke depression may be due in part to neuroprotective and neurogenesis properties via a common signaling pathway of CLS, such as the cAMP/CREB signaling pathway, with the primary beneficial actions of the drugs derived from improved monoamine function. This evidence concerns the gene CREB1 and Stroke.